中国现代医生杂志欢迎您.   今天是:          
章俏雷1 江锦红1 刘永华1 王晓丽1 江 妤1 叶琇锦2 方炳木1▲.伴有CEBPA双位点突变的急性髓系白血病临床特征及预后分析[J].中国现代医生,2021,59(4):42-45+49
伴有CEBPA双位点突变的急性髓系白血病临床特征及预后分析
Clinical features and prognostic analysis of acute myeloid leukemia with double CEBPA mutations
  
DOI:
中文关键词:  CEBPA 双位点突变  急性髓系白血病  临床特征  预后
英文关键词:Double CEBPA mutations  Acute myeloid leukemia  Clinical features  Prognosis
基金项目:浙江省基础公益研究计划项目(LGF19H080003);浙江省医学会临床科研资金项目(2018ZYC-A162);浙江省丽水市自筹类公益性技术应用研究项目(2019SJZC51)
作者单位
章俏雷1 江锦红1 刘永华1 王晓丽1 江 妤1 叶琇锦2 方炳木1▲ 1.温州医科大学附属第六医院 浙江省丽水市人民医院浙江丽水 3230002.浙江大学医学院附属第一医院浙江杭州 310003 
摘要点击次数: 52
全文下载次数: 125
中文摘要:
      目的分析伴有CEBPA 双位点突变的急性髓系白血病(AML)的临床特征及预后。方法 回顾性分析2013 年1 月至2019 年5 月浙江大学医学院附属第一医院及丽水市人民医院血液科连续收治的AML(非M3)患者1030 例,其中CEBPA 双位点突变AML 共75 例为试验组,非CEBPA 双位点突变AML 共955 例为对照组。比较两组患者的临床特征及预后差异。结果 试验组AML 患者FAB 分型中M4 比例明显高于对照组(P=0.004);试验组初诊PLT 水平低于对照组(P=0.041);试验组预后中等染色体核型比例明显高于对照组(P=0.001);试验组CD7 抗原阳性比例明显高于对照组(P<0.001);试验组患者早期死亡率为4.00%,低于对照组患者的13.10%(P=0.022),其预计5 年总生存(OS)率明显高于对照组(57.33% vs.30.99%,P<0.001);试验组中多因素分析显示,年龄≥60 岁、HGB<88.75 g/L 和不良染色体核型是预后不良的独立危险因素。结论试验组AML 患者因有较低的早期死亡率,其预后明显优于对照组患者;年龄≥60 岁、HGB<88.75 g/L 和不良染色体核型是CEBPA 双位点突变AML 患者预后不良的独立危险因素。
英文摘要:
      Objective To analyze the clinical features and prognosis of acute myeloid leukemia(AML) with double CEBPA mutations.Methods A retrospective analysis was made on 1030 consecutive AML (non-M3) patients admitted to the First Affiliated Hospital of Zhejiang University School of Medicine and the hematology department of Lishui Municipal People′s Hospital from January 2013 to May 2019,of which CEBPA double-site mutant AML (n=75) were the experimental group and non-CEBPA double-site mutant AML(n=955) were the control group.The clinical features and prognostic analysis of the two groups were compared.Results The proportion of M4 in FAB typing of AML patients in the experimental group was significantly higher than that in the control group (P=0.004).The PLT level in the experimental group was lower than that in the control group(P=0.041).The proportion of moderate chromosome karyotype in the experimental group was significantly higher than that in the control group(P=0.001).The positive rate of CD7 antigen in the experimental group was significantly higher than that in the control group (P<0.001).The early mortality rate of the patients in the experimental group was 4.00%,which was lower than that of the control group (13.10%) (P=0.022),and its estimated 5-year overall survival (OS) rate was significantly higher than that of the control group (57.33% vs 30.99%,P<0.001).Multivariate analysis in the experimental group showed that age ≥60 years old,HGB<88.75 g/L and poor karyotype were independent risk factors for poor prognosis.Conclusion The prognosis of AML patients in the experimental group is obviously better than that in the control group due to their lower early mortality rate.Age≥60 years old,HGB<88.75 g/L and poor chromosome karyotype are independent risk factors for poor prognosis of CEBPA double site mutant AML patients.
查看全文  查看/发表评论  下载PDF阅读器
关闭
    • 关键词 :
    • 中国医生
    • 中国现代医生
    • 中国临床医生
    • 中国医师
    • 主任医师
    • 中国医学
    • 中华医学
    • 中国医院
    • 中国医药
    • 中国医疗
    • 现代医生
    • 现代医学
    • 现代医药
    • 现代医院
    • 现代药物
    • 现代护理
    • 现代临床
    • 医学杂志
    • 药学杂志
    • 医药杂志
    • 医生杂志
    • 医师杂志
    • 医疗杂志
    • 医药期刊
    • 医学期刊
    • 医药卫生期刊
    • 医药论文
    • 医学论文
    • 科研论文
    • 职称论文
    function PdfOpen(url){ var win="toolbar=no,location=no,directories=no,status=yes,menubar=yes,scrollbars=yes,resizable=yes"; window.open(url,"",win); } function openWin(url,w,h){ var win="toolbar=no,location=no,directories=no,status=no,menubar=no,scrollbars=yes,resizable=no,width=" + w + ",height=" + h; controlWindow=window.open(url,"",win); } &et=3C06DB566315F8DCDF29664692BB4F1A89951333316E065AD52854242B7DEE39B9B0351168C395BCB4A7BBA1B8683E8C5612491F75EE3FAB6758105856D2966BFE2A86BF4C6FFF8E88BF70D74F203BDB97DEF5A8F14F3CE7C323E042C64893C1&pcid=A9DB1C13C87CE289EA38239A9433C9DC&cid=BB33F1C95224820A&jid=8EDAEC11C165015425CEEA15366CB0A7&yid=9475FABC7A03F4AB&aid=&vid=&iid=E158A972A605785F&sid=ECE8E54D6034F642&eid=878DA0318B495A2F&fileno=2021939&flag=1&is_more=0">